Acute promyelocytic leukemia harboring a STAT5B‐RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B‐RARA
Acute promyelocytic leukemia harboring a STAT5B‐RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B‐RARA
复制标题
DOI：
10.1111/j.1600-0609.2009.01324.x
复制
发表时间：
2009-11
影响因子：
3.1
通讯作者：
Eisaku Iwanaga;Miki Nakamura;T. Nanri;T. Kawakita;K. Horikawa;H. Mitsuya;N. Asou
中科院分区：
文献类型：
--
作者：
Eisaku Iwanaga;Miki Nakamura;T. Nanri;T. Kawakita;K. Horikawa;H. Mitsuya;N. Asou
致编辑：全反式维甲酸（ATRA）的引入是治疗具有特征性t（15;17）易位的急性早幼粒细胞白血病（APL）的重大突破（1，2）。我们怀着极大的兴趣阅读了关于患有STAT 5 B-RARa的APL患者的报告（3）。迄今为止，只有三名报告的APL患者携带STAT 5 B-RARa（3-6），因此，该特定亚型的临床特征、对治疗的反应及其发病机制仍有待确定。本研究描述了第四例携带STAT 5 B-RARa的APL患者。一位41岁的日本男性于2006年7月因瘀点及发烧而入住本院。他的血红蛋白为9.5 g/dL，血小板计数为51 · 10/L，白细胞计数为77.8 · 10/L，91.2%的早幼粒细胞异常（图1A）。早幼粒细胞CD 13、CD 33阳性，CD 34阴性，
To the Editor: Introduction of all-trans retinoic acid (ATRA) has been the major breakthrough in the treatment of acute promyelocytic leukemia (APL) with a characteristic t(15;17) translocation (1, 2). With a great interest we read the report regarding the APL patient with STAT5B-RARa (3). To date, there are only three reported APL patients who harbor the STAT5B-RARa (3–6), therefore, clinical features of this particular subtype, response to therapy and its pathogenesis remain to be determined. This study describes the fourth APL patient harboring the STAT5B-RARa. A 41-yr-old Japanese man was admitted to our hospital because of petechiae and fever in July 2006. His hemoglobin was 9.5 g ⁄dL, platelet count was 51 · 10 ⁄L, and leukocyte count was 77.8 · 10 ⁄L with 91.2% abnormal promyelocytes (Fig. 1A). Promyelocytes were positive for CD13 and CD33 but negative for CD34 and